<DOC>
	<DOCNO>NCT01286844</DOCNO>
	<brief_summary>GSK2190915 development oral controller treatment adult pediatric asthma . This study open label , single repeat dose escalation study , child asthma . It investigate pharmacokinetics GSK2190915 child , age 1 12 year old inclusive , determine dosage regimen GSK2190915 pediatric population adjust achieve approximately level systemic exposure safe effective adult .</brief_summary>
	<brief_title>GSK2190915 Pediatric Study</brief_title>
	<detailed_description>Subjects recruit 2 cohort , Cohort 1 child 4 year age less 12 year age cohort 2 child 1 year age le 4 year age . Cohort 1 subdivide , dependent subject 's weight , enable different dose regimen pharmacokinetic sample within cohort . There 3 schedule Pharmacokinetic Safety Review meeting , enable dose adjustment dose young subject study . Blood urine collect pharmacokinetic pharmacodynamic analysis . Safety assess measurement heart rate , blood pressure , ECG , safety laboratory data review adverse event . Subjects also perform PEF Spirometry assess capable study investigator .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Male premenarchial female subject age 1to &lt; 12 year screen eligible study . Investigator diagnose history asthma . Subject weight minimum 11kg 10th percentile age . Patients must control exist asthma treatment currently stable treatment , screen . Apart asthma , eczema rhinitis , subject healthy suffer significant medical condition . Subjects parents/guardians must able understand comply protocol requirement , instruction protocolstated restriction . Parents/guardians must ability read write . A signed date informed consent least one parent/guardian , , subject â‰¥ 7 year old accompanying inform assent subject prior admission study . AST ALT &lt; 2xULN . Subjects change asthma medication , dose regime within 4 week screen Administration anti leukotriene therapy 14 day screen study . Any medical condition circumstance make volunteer unsuitable participation study . Any clinically relevant abnormality identify screen medical assessment . Culturedocumented suspected bacterial viral infection upper low respiratory tract , sinus middle ear resolve within 4 week screen lead change asthma management . Administration vaccination within 2 week screen study Parent/guardian history psychiatric disease , intellectual deficiency , substance abuse , condition limit validity consent participate study . Any adverse reaction include immediate delay hypersensitivity component study drug A subject eligible study he/she immediate family member participate Investigator , subInvestigator , study coordinator , employee participate Investigator . Children ward state government . The subject screening QTc value &gt; 450msec , PR interval outside range 120 220msec ECG suitable QT measurement .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>